AGENTIX is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of metabolic diseases including type 2 diabetes mellitus, chronic obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). AGENTIX has acquired and is commencing clinical evaluation of certain therapeutic assets exclusively licensed from the National Heath Research Institute Taiwan (NHRI) and Research Triangle Institute (RTI), dba RTI International. For more information, please visit: www.agentixcorp.com.
Company profile
Ticker
AGTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
FairWind Energy Inc.
SEC CIK
Corporate docs
Subsidiaries
GSL Healthcare, Inc. • Applied Biopharma LLC • Agentix Australia Pty Ltd ...
IRS number
462876282
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
14 Feb 24
10-Q
2024 Q2
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
10-Q
2024 Q1
Quarterly report
22 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-K
2023 FY
Annual report
13 Jul 23
NT 10-K
Notice of late annual filing
29 Jun 23
10-Q
2023 Q3
Quarterly report
14 Feb 23
10-Q
2023 Q2
Quarterly report
14 Nov 22
10-Q
2023 Q1
Quarterly report
11 Aug 22
Latest ownership filings
SC 13D/A
Winterhalter Michael
22 Sep 20
SC 13G/A
Puzzo Thomas E
22 Sep 20
SC 13D
Stevens Scott B
26 May 20
SC 13D/A
Winterhalter Michael
26 May 20
SC 13G
Puzzo Thomas E
26 May 20
3
Thomas E Puzzo
22 May 20
4
Change in insider ownership
21 May 20
4
Michael Winterhalter
21 May 20
4
Change in insider ownership
5 Nov 19
4
Scott B Stevens
5 Nov 19
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Aug 21 | Aug 20 | Aug 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.54 k | 27.54 k | 27.54 k | 27.54 k | 27.54 k | 27.54 k |
Cash burn (monthly) | (no burn) | (no burn) | 117.72 k | 128.09 k | (no burn) | 4.01 k |
Cash used (since last report) | n/a | n/a | 807.68 k | 878.83 k | n/a | 27.54 k |
Cash remaining | n/a | n/a | -780.15 k | -851.30 k | n/a | 1.35 |
Runway (months of cash) | n/a | n/a | -6.6 | -6.6 | n/a | 0.0 |